



Medical Educational Requests:

Mallinckrodt Pharmaceuticals is committed to supporting independent, high-quality educational programs and clinical training for healthcare professionals (HCPS) including conduct of clinically relevant independent research that contributes to the improvement of patient care in the therapeutic areas in which the business has research and commercial interests.

Mallinckrodt Pharmaceuticals provides financial assistance to support accredited or unaccredited educational symposia, seminars and/or sessions directed at certified healthcare professionals, where the grant recipient is solely responsible for developing the content and managing the educational program.

The Grants Review Committee meets regularly to review all submissions. Grant applications must be received at least sixty (60) days prior to the activity start date to be considered eligible for funding.

If the grant is approved, Mallinckrodt Pharmaceuticals requires that a fully executed Letter of Agreement (LOA), signed by the grant requestor and Mallinckrodt, be completed prior to the commencement of the program. In addition, grant recipients are required to confirm the completion of the program and provide documentation of how funds were used.

Each educational grant awarded must adhere to and be compliant with:

- FDA Final Guidance on Industry-Supported Scientific and Educational Activities
- Office of Inspector General (OIG) Guidelines
- Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support
- Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals
- American Medical Association (AMA) Ethical Guidelines for Gifts to Physicians from Industry
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- MedTech Europe
- Other relevant guidelines and regulations as applicable in country of Requestor

Mallinckrodt Pharmaceuticals' Therapeutic Areas of Interest

- **Regenerative Medicine**
 - Regenerative approaches to treating severe burns
 - Regenerative approaches to autografting alternatives
 - Support scientific understanding of regenerative medicine as it pertains to wound healing in burns
- **Extracorporeal Photopheresis**
 - Solid Organ Transplant (SOT) Kidney, Heart and Lung
 - Treatment of Systemic Sclerosis
 - Treatment of early stage CTCL
 - Combination treatment within CTCL
 - Treatment of GvHD
 - 1st line treatment GvHD (+/- steroids)

- Treatment of Checkpoint-inhibitor induced irAEs
- Mechanism of action
- **Nitric-Oxide**
 - Neonatal Critical Care
 - Acute Respiratory Distress Syndrome
 - Anti-infective Mechanisms
 - Cardiac Surgery (e.g., congenital heart disease, left ventricular assist devices)
 - Inhaled Nitric Oxide Delivery System Features and Safety
 - Lung Transplant (Japan only)
 - Pulmonary Hypertension in Special Populations
- **Complications of Cirrhosis**
 - Esophageal Variceal Hemorrhage (EVH)
 - Septic Shock
 - Refractory Ascites
 - Hepatorenal Syndrome (HRS)

Mallinckrodt is no longer accepting medical education grants that focus on the following therapeutic areas.

- **IV Acetaminophen**
- **Immunology/Rare Diseases**
 - Nephrology
 - Neurology
 - Pulmonology
 - Ophthalmology
 - Rheumatology

Mallinckrodt is committed to transparency in its interactions with healthcare professionals and health care organizations/institutions consistent with applicable laws and/or codes relating to the pharmaceutical industry.

For questions, please email our Medical Education Department at EdGrants@mnk.com